Clinical and economic evidence generation across rare diseases is challenging due to intrinsic disease characteristics, misalignment on treatment costs, and inadequate traditional evaluation frameworks. Therefore, rare disease products face unique payer challenges, which need to be comprehensively mapped and understood to optimize pricing and market access potential.
To address payer challenges in rare diseases, it is important to take a multi-pronged approach. This includes proactively informing payers on the unique characteristics of rare diseases, shifting their evaluation perspectives beyond the typical frameworks used for more common conditions, and disassociating them from economic models that may not be well-suited for the rare disease context.
Our Life Sciences practice is dedicated to providing tailored solutions to help maximize value and drive towards equitable access to life-saving treatments.
Click here to see the infographic.
